Sugi Predict

Sugi Predict / Targets / FLI1

FLI1

Friend leukemia integration 1 transcription factor · Q01543 · FLI1 on Sugi Atlas →

491 patent compounds predicted against FLI1, 357 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15337231 SCHEMBL15337231 1.00 6/20
SCHEMBL15337266 SCHEMBL15337266 1.00 6/20
SCHEMBL15337280 SCHEMBL15337280 1.00 6/20
SCHEMBL17679814 SCHEMBL17679814 1.00 6/20
SCHEMBL17679816 SCHEMBL17679816 1.00 6/20
SCHEMBL25140493 SCHEMBL25140493 0.80 6/20
SCHEMBL15337268 SCHEMBL15337268 0.78 6/20
SCHEMBL22199725 SCHEMBL22199725 0.77 6/20
SCHEMBL15337274 SCHEMBL15337274 0.75 6/20
SCHEMBL19419580 SCHEMBL19419580 0.75 6/20
SCHEMBL19620144 SCHEMBL19620144 0.75 6/20
SCHEMBL19424045 SCHEMBL19424045 0.73 6/20
SCHEMBL13253323 SCHEMBL13253323 0.73 6/20
SCHEMBL13253325 SCHEMBL13253325 0.73 6/20
SCHEMBL13253326 SCHEMBL13253326 0.73 6/20
SCHEMBL13253331 SCHEMBL13253331 0.73 6/20
SCHEMBL17669239 SCHEMBL17669239 0.73 6/20
SCHEMBL17679855 SCHEMBL17679855 0.73 6/20
SCHEMBL17679856 SCHEMBL17679856 0.73 6/20
SCHEMBL29810788 SCHEMBL29810788 0.73 6/20

Clinical trials — most relevant to FLI1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents PHASE3ACTIVE_NOT_RECRUITING
Timed-Sequential Induction in CBF-AML PHASE3COMPLETED
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma PHASE3UNKNOWN
First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3) PHASE2COMPLETED
Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma PHASE1/PHASE2WITHDRAWN
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Decitabine in Treating Patients With Myelofibrosis PHASE2ACTIVE_NOT_RECRUITING
Lurbinectedin in FET-Fused Tumors PHASE1/PHASE2RECRUITING
Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML PHASE1COMPLETED
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML PHASE1COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) PHASE1COMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Association of Formaldehyde Exposure to Myeloid Leukemia in Workers in Guangdong, China nanCOMPLETED
Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia nanUNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. nanUNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Studying Gene Expression in Tissue Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia nanCOMPLETED
S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia nanCOMPLETED
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia nanRECRUITING
Molecular Disease Profile of Hematological Malignancies nanUNKNOWN
Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML) nanUNKNOWN
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a FLI1 binder may also engage these)

ProteinNameSimilarity
Q29RS8 — 1.000 Q29RS8 →
P41157 — 1.000 P41157 →
P26323 — 1.000 P26323 →
Q90837 — 1.000 Q90837 →
ERG Transcriptional regulator ERG 1.000 landscape →
P81270 — 1.000 P81270 →
P97360 — 0.991 P97360 →
C1GR85 — 0.990 C1GR85 →
PAX2 Paired box protein Pax-2 0.990 landscape →
Q18579 — 0.990 Q18579 →
Q9XSK8 — 0.990 Q9XSK8 →
Q5R7I3 — 0.989 Q5R7I3 →
A3FEM2 — 0.989 A3FEM2 →
P24610 — 0.989 P24610 →
Q22829 — 0.989 Q22829 →
ETV6 Transcription factor ETV6 0.989 landscape →
P41935 — 0.989 P41935 →
Q8STF6 — 0.989 Q8STF6 →
Q5A7S7 — 0.988 Q5A7S7 →
Q62661 — 0.988 Q62661 →
Q90268 — 0.988 Q90268 →
Q91905 — 0.988 Q91905 →
O74252 — 0.988 O74252 →
Q7Z353 — 0.988 Q7Z353 →
P51558 — 0.988 P51558 →
P32114 — 0.988 P32114 →
Q6E3D4 — 0.988 Q6E3D4 →
O17087 — 0.988 O17087 →
Q9JJP2 — 0.988 Q9JJP2 →
P50574 — 0.987 P50574 →